Evaluation of Respiratory Muscle Sarcopenia in Obstructive Sleep Apnea Syndrome
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Obstructive Sleep Apnea (OSAS). Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Turkey (Türkiye)
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
OSAS is a disease characterized by repeated interruptions and restarts of breathing during sleep. Respiratory muscle sarcopenia is a condition in which the muscle strength of the diaphragm and other respiratory auxiliary muscles decreases, resulting in a decrease in breathing effort. Decreased respiratory effort is an important indicator of OSAS. Age, presence of chronic disease, and obesity increase the presence and severity of respiratory sarcopenia. If OSAS is left untreated, it leads to cardiovascular diseases, dementia, Alzheimer's and even death in early adulthood. In recent years, studies have shown that continuous positive airway pressure (CPAP), as well as healthy behavior development, preventive health and exercise measures, are important in the management of these diseases. There is no research in the literature on the evaluation of respiratory muscle sarcopenia in OSAS patients. This study aims to evaluate respiratory muscle sarcopenia in OSAS based on a concrete value reflecting respiratory muscle strength and/or volume.
Detailed description
In the study, respiratory muscle sarcopenia will be evaluated in OSAS patients. It will be evaluated whether the expiratory pressure value, peek flow meter value and 6-minute walking distance are predictors of respiratory sarcopenia for OSAS.
Primary outcome measures
- Anthropometric measurement [Time frame: 1 year]
- BOdy mass measurement [Time frame: 1 year]
- Hand Grip strength [Time frame: 1 year]
- Walking speed [Time frame: 1 year]
- Respiratory muscle strength: [Time frame: 1 year]
- Expiratory flow rate [Time frame: 1 year]
- Respiratory function test [Time frame: 1 year]
Secondary outcome measures (1)
- Functional capacity [Time frame: 1 year]
Eligibility criteria
Inclusion criteria
- Diagnosed with normal-mild-medium-severe OSAS
- 18 years and above
- Turkish speaking patients will be included.
Exclusion criteria
- Pregnancy,
- Latent autoimmune diabetes,
- Chronic renal failure,
- Active or serious infections,
- Liver failure,
- Recent major cardiovascular events,
- Unstable angina, heart failure (NYHA III-IV),
- Patients with neurological or musculoskeletal disorders that create limitations in walking and performing tests
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
Turkey (Türkiye) · 1 center
- Tarsus University — Mersin
Identifiers
NCT: NCT06783998 · 2025/01